info@iozk.de
  • Startseite
  • Das IOZK
    • Philosophie
    • Team
    • Behandlungszentrum
    • Laboratorien
    • Karriere
    • Anreise und Übernachtung
  • Die IOZK Immuntherapie
    • IOZK-Immuntherapie
    • IO-VAC Impfstoff
    • Behandlungsablauf
    • Therapiekosten
    • FAQ
  • Fachwissen
    • IOZK Publikationen
    • Int. Publikationen
    • Wissenswertes
    • IOZK Podcasts
  • Aktuelles
  • Kontakt
  • Menü Menü

Prof. Dr. rer. nat. Volker Schirrmacher

Wissenschaftlicher Leiter der Tumorimmunologie am IOZK

Krebsforscher und Immunologe

Prof. Dr. rer. nat. Volker Schirrmacher erhielt 1976 einen Ruf an das Deutsche Krebsforschungszentrum (DKFZ) in Heidelberg als Wissenschaftlicher Rat und Professor für Immunologie. 1979 habilitierte er sich in Immunologie in Heidelberg und 1986 wurde er ordentlicher Professor. Am DKFZ leitete er die Abteilung zelluläre Immunologie bis zu seiner Emeritierung 2008.

Seit 2008 ist er am IOZK Wissenschaftlicher Leiter der Tumorimmunologie. Sein Wissenschaftliches Œuvre umfasst fast 400 Veröffentlichungen in internationalen Fachzeitschriften.

1987 und 1988 war er Vorsitzender der Sektion Experimentelle Krebsforschung bei der Deutschen Krebsgesellschaft und 1989/80 Präsident der Metastasis Research Society. 2003 und 2004 vertrat er Deutschland bei der European Association of Cancer Research (EACR). Von 2009 bis 2011 war er Präsident der Europäischen Gesellschaft für Angewandte Immunologie e.V. (EGAI).

1982 erhielt er den Aronson-Preis und den Meyenburg-Preis und 1988 den Deutschen Krebspreis.

Er ist ein international anerkannter Pionier der Immuntherapie bei Krebs mit dem Schwerpunkt onkolytische Viren. Gemeinsam mit den Naturwissenschaftlern und Ärzten am IOZK arbeitet er an der systematischen Integration neuer wissenschaftlicher Erkenntnisse zur Weiterentwicklung der IOZK-Immuntherapie.

  • Weitere Informationen auf Wikipedia

„Viren sind als Auslöser verschiedener Krankheiten bekannt. Weniger bekannt ist jedoch, dass bestimmte Viren für die Behandlung von Krebs eingesetzt werden. Vor über 100 Jahren beobachteten Ärzte erstmals, dass Patienten nach Virusinfektionen von ihrem Krebsleiden geheilt waren.“

Prof. Dr. rer. nat. Volker Schirrmacher

Sammlung: Wissenschaftliche Beiträge und internationale Publikationen von Volker Schirrmacher

The Complexity of Malignant Glioma Treatment

2025-03-04
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2025-03-04 / Cancers (Basel) 2025 Mar;17(5) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2025-03-04 / Cancers (Basel) 2025 Mar;17(5)2025-03-04 00:00:002025-03-17 07:36:12The Complexity of Malignant Glioma Treatment

Interview mit Prof. Dr. Volker Schirrmacher im Klassik Radio

2024-07-04
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 arndslegers https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg arndslegers2024-07-04 10:34:312024-11-18 10:38:45Interview mit Prof. Dr. Volker Schirrmacher im Klassik Radio

Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution

2024-03-28
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2024-03-28 / Biomedicines 2024 Mar;12(4) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2024-03-28 / Biomedicines 2024 Mar;12(4)2024-03-28 00:00:002024-04-30 08:35:31Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution

Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients

2023-10-19
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-10-19 / Methods Cell Biol 2024;183:51-113 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-10-19 / Methods Cell Biol 2024;183:51-1132023-10-19 00:00:002024-04-20 10:47:17Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients

Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?

2023-07-28
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?

The Application of Evidence-Based Medicine in Individualized Medicine

2023-06-23
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-06-23 / Biomedicines 2023 Jun;11(7) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-06-23 / Biomedicines 2023 Jun;11(7)2023-06-23 00:00:002024-04-17 15:04:06The Application of Evidence-Based Medicine in Individualized Medicine

Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience

2023-02-13
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2023-02-13 / Cancers (Basel) 2023 Feb;15(4) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy

2022-10-27
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-10-27 / Int J Mol Sci 2022 Oct;23(21) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)2022-10-27 00:00:002023-01-31 13:01:45Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

2022-02-16
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-02-16 / Genes Immun 2022 Feb; https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-02-16 / Genes Immun 2022 Feb;2022-02-16 00:00:002022-02-21 07:49:56Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

2020-12-24
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-12-24 / Cancers (Basel) 2020 Dec;13(1) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)2020-12-24 00:00:002021-11-15 13:17:14Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism

2020-11-22
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-11-22 / Biomedicines 2020 Nov;8(11) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-11-22 / Biomedicines 2020 Nov;8(11)2020-11-22 00:00:002021-11-15 19:49:33Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism

Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

2020-07-23
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-07-23 / Biomedicines 2020 Jul;8(8) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-07-23 / Biomedicines 2020 Jul;8(8)2020-07-23 00:00:002021-11-15 19:51:32Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

2020-06-30
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)

2020-06-02
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2020-06-02 12:45:162020-06-02 13:07:50IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)

Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

2020-05-19
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-05-19 / Medicines (Basel) 2020 May;7(5) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

Prof. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zur Immuntherapie

2020-03-16
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2020-03-16 17:41:482020-05-20 11:33:51Prof. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zur Immuntherapie

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

2020-03-16
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-03-16 / Biomedicines 2020 Mar;8(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-03-16 / Biomedicines 2020 Mar;8(3)2020-03-16 00:00:002021-11-15 19:52:47Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection

2020-03-06
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-03-06 / Biomedicines 2020 Mar;8(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-03-06 / Biomedicines 2020 Mar;8(3)2020-03-06 00:00:002021-11-15 17:52:40New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

2019-08-30
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2019-08-30 / Biomedicines 2019 Aug;7(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

Professor Volker Schirrmacher vom Kölner IOZK eröffnet die Tagung an der Universität zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie.

2019-05-22
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/05/Schirrmacher_Vortrag.jpg 1000 1500 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2019-05-22 06:52:582019-07-15 15:46:53Professor Volker Schirrmacher vom Kölner IOZK eröffnet die Tagung an der Universität zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie.

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

2018-12-10
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2018-12-10 / Int J Oncol 2019 Feb;54(2):407-419 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2018-12-10 / Int J Oncol 2019 Feb;54(2):407-4192018-12-10 00:00:002021-11-15 20:14:26From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher

2018-12-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2018-12-01 18:15:082021-11-15 17:54:58International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher

IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“

2018-07-24
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 root https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg root2018-07-24 18:56:262020-05-27 11:18:50IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“

IOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin

2018-05-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2018-05-01 11:21:402019-09-09 11:30:03IOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin

Buch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy

2018-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2018-01-01 16:18:592019-02-10 11:33:47Buch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy

IOZK Artikel im International Journal of Molecular Sciences von Prof. Schirrmacher über die Rolle des Newcastle Disease Virus im Rahmen der Tumorimpfung,

2017-07-10
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2017-07-10 11:44:412019-07-15 16:57:22IOZK Artikel im International Journal of Molecular Sciences von Prof. Schirrmacher über die Rolle des Newcastle Disease Virus im Rahmen der Tumorimpfung,

Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients

2017-05-20
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2017-05-20 / Int J Mol Sci 2017 May;18(5) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2017-05-20 / Int J Mol Sci 2017 May;18(5)2017-05-20 00:00:002021-11-15 16:51:51Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients

IOZK Artikel von Prof. Schirrmacher in „Deutsche Zeitschrift für Onkologie“ über die Grundlagen der Immuntherapie

2017-05-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2017-05-01 11:52:062019-02-10 12:10:59IOZK Artikel von Prof. Schirrmacher in „Deutsche Zeitschrift für Onkologie“ über die Grundlagen der Immuntherapie

IOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe

2017-03-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2017-03-01 12:12:242020-05-27 11:24:21IOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe

Artikel von Prof Schirrmacher in Biomedicines: „Fifty Years of Clinical Application of Newcastle Disease Virus“

2016-08-10
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2016-08-10 12:33:022020-05-27 11:26:48Artikel von Prof Schirrmacher in Biomedicines: „Fifty Years of Clinical Application of Newcastle Disease Virus“

Bericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark

2015-10-12
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2015-10-12 16:50:102019-02-12 16:51:19Bericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

2015-10-05
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-712015-10-05 00:00:002021-11-15 16:52:53Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

IOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs 

2015-06-15
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2015-06-15 17:07:482020-05-27 11:39:56IOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs 

Beitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift „Skriptum“

2015-06-12
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2015-06-12 17:06:232019-02-12 17:07:27Beitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift „Skriptum“

Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report

2015-05-28
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-05-28 / Immunotherapy 2015;7(8):855-60 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report

Prof. Dr. Schirrmacher veröffentlicht E-Book: Harnessing Oncolytic Virus-mediated Antitumor Immunity

2014-11-30
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2014-11-30 17:15:002019-02-12 17:15:38Prof. Dr. Schirrmacher veröffentlicht E-Book: Harnessing Oncolytic Virus-mediated Antitumor Immunity

Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study

2014-10-06
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-10-06 / Int. J. Oncol. 2015 Jan;46(1):71-7 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-10-06 / Int. J. Oncol. 2015 Jan;46(1):71-72014-10-06 00:00:002021-11-15 16:54:44Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study

Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report

2014-10-06
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-24062014-10-06 00:00:002021-11-16 07:53:33Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report

Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies

2014-09-11
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-09-11 / Front Oncol 2014;4:224 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-09-11 / Front Oncol 2014;4:2242014-09-11 00:00:002021-11-15 16:55:17Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies

Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

2014-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-302014-01-01 00:00:002021-11-15 16:55:45Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

2013-07-02
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-752013-07-02 00:00:002021-11-15 16:56:11Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future

2013-02-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-02-01 / BioDrugs 2013 Feb;27(1):35-53 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-02-01 / BioDrugs 2013 Feb;27(1):35-532013-02-01 00:00:002021-11-15 16:56:59Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future

Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation

2012-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2012-01-01 / Methods Mol. Biol. 2012;797:177-204 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2012-01-01 / Methods Mol. Biol. 2012;797:177-2042012-01-01 00:00:002021-11-15 16:57:22Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation

Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity

2011-11-16
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-502011-11-16 00:00:002021-11-15 16:57:44Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity

Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus

2011-10-04
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-982011-10-04 00:00:002021-11-15 16:58:12Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus

Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus

2011-05-09
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-5042011-05-09 00:00:002021-11-15 16:58:35Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus

Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity

2011-03-17
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-292011-03-17 00:00:002021-11-15 16:59:03Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity

Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity

2010-12-18
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2010-12-18 / Vaccine 2011 Feb;29(6):1185-93 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2010-12-18 / Vaccine 2011 Feb;29(6):1185-932010-12-18 00:00:002021-11-15 16:59:23Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity

Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25

2010-12-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-522010-12-01 00:00:002021-11-15 16:59:47Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25

Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine

2010-11-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-172010-11-01 00:00:002021-11-15 17:00:11Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine

The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination

2010-08-13
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2010-08-13 / Vaccine 2010 Oct;28(42):6891-900 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2010-08-13 / Vaccine 2010 Oct;28(42):6891-9002010-08-13 00:00:002021-11-15 17:00:34The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination

Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus

2009-09-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-222009-09-01 00:00:002021-11-15 17:00:58Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus

Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase

2009-06-10
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-06-10 / J. Virol. 2009 Aug;83(16):8108-212009-06-10 00:00:002021-11-15 17:01:25Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase

Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus

2009-04-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-822009-04-01 00:00:002021-11-15 17:01:56Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus

Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus

2009-04-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-622009-04-01 00:00:002021-11-15 17:02:15Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008

2009-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-662009-01-01 00:00:002021-11-15 17:02:36Randomized clinical studies of anti-tumor vaccination: state of the art in 2008

Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer

2009-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-01-01 / Methods Mol. Biol. 2009;542:565-605 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-01-01 / Methods Mol. Biol. 2009;542:565-6052009-01-01 00:00:002021-11-15 17:03:01Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer

Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study

2008-11-08
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study

Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2

2008-10-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-322008-10-01 00:00:002021-11-15 17:03:44Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2

Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy

2008-06-05
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-802008-06-05 00:00:002021-11-15 17:04:06Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy

Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer

2008-06-03
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-7 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-72008-06-03 00:00:002021-11-15 17:04:28Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

2008-05-17
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-92008-05-17 00:00:002021-11-15 17:04:52Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins

2008-04-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-892008-04-01 00:00:002021-11-15 17:05:15An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins

Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007

2008-02-13
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-72008-02-13 00:00:002021-11-15 17:05:45Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007

Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application

2007-11-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-19 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-192007-11-01 00:00:002020-06-23 09:32:35Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

2007-10-04
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-492007-10-04 00:00:002020-06-23 09:33:03Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma

2007-07-24
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-99 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-992007-07-24 00:00:002020-06-23 09:34:42Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma

Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ

2006-12-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-3 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-32006-12-01 00:00:002020-06-23 09:36:05Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

2006-07-15
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-382006-07-15 00:00:002020-06-23 09:36:30Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

2006-02-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-672006-02-01 00:00:002020-06-23 09:36:57A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein

2005-08-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-842005-08-01 00:00:002020-06-23 09:37:35Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein

T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine

2005-03-31
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2005-03-31 / Vaccine 2005 Mar;23(19):2439-53 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2005-03-31 / Vaccine 2005 Mar;23(19):2439-532005-03-31 00:00:002020-06-23 09:38:03T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine

Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus

2005-03-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-3032005-03-01 00:00:002020-06-23 09:38:35Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus

Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein

2005-02-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-9 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-92005-02-01 00:00:002020-06-23 09:39:16Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein

Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

2004-11-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-612004-11-01 00:00:002020-06-23 09:39:52Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

2004-10-30
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-982004-10-30 00:00:002020-06-23 09:40:23Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit

2004-09-27
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-812004-09-27 00:00:002020-06-23 09:41:00Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit

High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules

2004-08-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-302 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-3022004-08-01 00:00:002020-06-23 09:41:28High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules

Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus

2004-03-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-342004-03-01 00:00:002020-06-23 09:42:15Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus

TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus

2003-02-15
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-21 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-212003-02-15 00:00:002020-06-23 09:42:47TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus

Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo

2003-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-83 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-832003-01-01 00:00:002020-06-23 09:43:21Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo

Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer

2003-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-802003-01-01 00:00:002020-06-23 09:43:48Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer

Editorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“

2002-12-12
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2002-12-12 18:49:432019-02-12 18:50:31Editorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“

Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis

2002-07-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2002-07-01 / Int. J. Oncol. 2002 Jul;21(1):85-93 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2002-07-01 / Int. J. Oncol. 2002 Jul;21(1):85-932002-07-01 00:00:002020-06-23 09:44:19Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis

Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells

2002-02-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2002-02-01 / Int. J. Oncol. 2002 Feb;20(2):247-53 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2002-02-01 / Int. J. Oncol. 2002 Feb;20(2):247-532002-02-01 00:00:002020-06-23 09:44:50Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells

Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects

2001-05-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-522001-05-01 00:00:002020-06-23 09:45:33Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects

Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures

1999-02-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-15 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-151999-02-01 00:00:002020-06-23 09:46:02Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

1999-01-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-731999-01-01 00:00:002020-06-23 09:46:30Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus

1998-12-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-15 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-151998-12-01 00:00:002020-06-23 09:46:52Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

1997-04-01
Weiterlesen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-661997-04-01 00:00:002020-06-23 09:47:26Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

Weitere Informationen zu diesem Thema:

  • Team
  • Literatur von und über Volker Schirrmacher
  • Viren gegen Krebs
  • Bedeutung von dendritischen Zellen
  • TikTok
  • Instagram
  • LinkedIn
  • YouTube
  • Podcast
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland

T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de

Das IOZK

  • Philosophie
  • Team
  • Behandlungszentrum
  • Laboratorien
  • Karriere
  • Anreise und Übernachtung

Die IOZK Immuntherapie

  • IOZK-Immuntherapie
  • Der IO-VAC® Impfstoff
  • Behandlungsablauf
  • Therapiekosten
  • FAQ

IOZK Publikationen

  • The Complexity of Malignant Glioma Treatment
  • Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
  • Neue IOZK Veröffentlichung zum Thema Liquid Biopsy
© 2025 IOZK Immun-Onkologisches Zentrum Köln
  • Impressum
  • Datenschutzerklärung
  • Cookie-Einstellungen
  • Presse
Nach oben scrollen